News

Cabaletta Bio is getting set to launch a clinical trial testing its cell therapy resecabtagene autoleucel (rese-cel) in people with relapsing and progressive forms of multiple sclerosis (MS). The company sought permission last year from the U.S. Food and Drug Administration (FDA) to start the study. Once such…

For women with multiple sclerosis (MS), disability starts to worsen significantly faster after menopause, according to a new study. “The study shows that menopause represents a unique factor in MS progression, even when we take into consideration the effects of aging,” Riley Bove, MD, study co-author at the University…

Patient enrollment has been completed ahead of schedule in a Phase 2 clinical trial evaluating Contineum Therapeutics‘ PIPE-307, an oral therapy aiming to restore myelin — a process known as remyelination — in people with relapsing-remitting multiple sclerosis (RRMS), the company announced. The VISTA trial (NCT06083753), launched…

A Phase 1 clinical trial that is investigating a new vaccine against the Epstein-Barr virus (EBV), a well-established risk factor for developing multiple sclerosis (MS), in healthy volunteers has dosed its first participant. The vaccine, called MDX2201, is being developed by Modex Therapeutics, an Opko Health company,…

Immunic Therapeutics says it remains “on track” in testing its multiple sclerosis treatment candidate vidofludimus calcium in twin Phase 3 clinical trials with people who have relapsing disease — and in the Phase 2 CALLIPER study involving those with progressive forms of MS. Indeed, in a new company…

OCS-05, an experimental medication that Oculis is developing to treat acute optic neuritis, a common symptom of multiple sclerosis (MS) that can lead to vision loss, was well tolerated and improved measures of vision and eye health in a Phase 2 clinical trial. The ACUITY study (NCT04762017) included…

IRX4204, a compound that Io Therapeutics is developing to treat neurological diseases, facilitated myelin repair and improved walking abilities in a mouse model of multiple sclerosis (MS) in a recent study, scientists report. “Our findings support the therapeutic potential of IRX4204 to promote functional neurologic recovery in…

Treatment with Tecfidera (dimethyl fumarate) significantly reduces relapse rates for people with multiple sclerosis (MS), and most MS patients on the approved therapy remain free from disability progression for several years. That’s according to a final analysis from the Phase 4 ESTEEM clinical trial (NCT02047097), which tracked…

In the five years leading up to a multiple sclerosis (MS) diagnosis, children and adolescents often experience obesity and symptoms such as sensory disturbances and vision problems — potential early signs of MS that could help in diagnosing the condition, according to a new study. Indeed, the study reports…

Most treatments for multiple sclerosis (MS) don’t increase the risk of major problems when used during pregnancy, an analysis showed. “We found that most therapies were not associated with an increased risk of miscarriage, premature birth or major birth defects,” Kerstin Hellwig, MD, study co-author and MS specialist at…

The team at Multiple Sclerosis News Today has brought our audience the latest news about treatments, scientific research, and clinical trials in multiple sclerosis (MS) throughout 2024. Here is a list of the top 10 most-read articles we published this year. We look forward to continuing to serve…

People with multiple sclerosis (MS) show significant differences between actual age and vascular age, an indicator of heart and blood vessel health, even if they don’t have any cardiovascular disease, a study found. The difference became more pronounced with the presence of additional cardiovascular diseases, reaching a peak among…

Men with multiple sclerosis (MS) who started on high-efficacy disease-modifying therapies (DMTs) experienced significantly fewer relapses than those who started with moderate-efficacy DMTs, according to real-world claims analysis involving more than 10,000 U.S. patients. “No significant difference in relapse was found among females,” researchers wrote. “This observation highlights…

The incidence of late-onset multiple sclerosis (LOMS), a form of multiple sclerosis (MS) that begins after age 50, has risen steadily between 2005 and 2020, particularly among people in their 60s, scientists in Italy report. “Our study is the first population-based study describing the IR [incidence rate] of LOMS…

Exercise effectively reduces fatigue and improves muscular fitness in people with multiple sclerosis (MS), though the optimal exercise type and dose differ for each outcome, according to a meta-analysis of published studies involving more than 3,500 patients. Mind-body exercise, which combines physical movement, mental focus, and controlled breathing, was…

IMP761, an experimental immunotherapy Immutep is developing for multiple sclerosis (MS) and other autoimmune conditions, has shown a promising safety profile in an ongoing Phase 1 clinical trial  in healthy volunteers, with no treatment-related side effects reported to date, the company said. The first-in-human Phase 1 trial…

About four in five adults with stable multiple sclerosis (MS) for at least five years remained free of disease activity after stopping first-line treatment with a disease-modifying therapy (DMT), according to a study based on data from the DOT-MS clinical trial. Still, disease activity reemerged in roughly 20%…

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Sanofi’s BTK inhibitor candidate tolebrutinib for the treatment of adults with nonrelapsing secondary progressive multiple sclerosis (SPMS). According to Sanofi, tolebrutinib is the first investigational BTK inhibitor with the ability to reach the brain…

A specific type of brain lesion called a paramagnetic rim lesion, or PRL, is associated with worse disability over time in people with multiple sclerosis (MS), but available disease-modifying therapies (DMT) can lower the chances of the appearance of these lesions, according to two studies published by scientists…

An interplay between genetic and environmental risk factors, including tobacco smoke exposure, affects brain development in early childhood, which could increase the likelihood a person will develop multiple sclerosis (MS), according to a recent study. Among young children in the Netherlands, being at a high genetic risk for MS,…

Blood levels of neurofilament light chain (NfL) — a biomarker of nerve cell damage used in multiple sclerosis (MS) research — are influenced by factors such as age, body mass index (BMI), and storage conditions of the blood samples, according to a recent report. Such factors may need to…

Bionxt Solutions is preparing to launch a pilot clinical trial to compare BNT23001, its new sublingual, or under-the-tongue, formulation of cladribine, to the original medication Mavenclad to treat multiple sclerosis (MS). Mavenclad is a tablet formulation of cladribine that’s approved for adults with relapsing forms of MS. The…

Vaccination does not increase the risk of multiple sclerosis (MS) in children and adolescents within five years, a study found. Instead, there was a trend toward a lower risk of pediatric-onset MS in vaccinated children. This in line with earlier findings that vaccination is not a risk factor for…

Nabiximols and other cannabis-based preparations sometimes used with multiple sclerosis (MS) appear to work well for controlling spasticity, a common disease symptom that occurs when muscles stiffen or tighten, a meta-analysis of findings in published studies reported. Larger studies into cannabis-based treatments of spasticity for these patients…

Tiziana Life Sciences is expanding its Phase 2 clinical trial testing foralumab nasal spray for the treatment of nonactive secondary progressive multiple sclerosis (SPMS), with six additional clinical sites across the northeastern region of the U.S. The new sites, all at top U.S. institutions, bring together leaders in…

Children with multiple sclerosis (MS) who come from poorer families or other disadvantageous circumstances tend to have more inflammation and irreversible brain tissue loss, a new study reports. “Our findings suggest that social disadvantage in childhood can have lasting effects on MS severity,” Kimberly A. O’Neill, MD, study coauthor…

Hospitalization for severe COVID-19 is significantly associated with a twofold higher risk of developing multiple sclerosis (MS), according to a study involving nearly the entire population of Sweden. No increased risk of MS was found among those who tested positive for SARS-CoV-2, the virus that causes COVID-19, or received…

People with multiple sclerosis (MS) who undergo an autologous hematopoietic stem cell transplant (HSCT) — which uses a patient’s own stem cells — face unique physical and emotional challenges at every stage of the process, from balancing hope and fear when deciding on moving forward with the treatment…

Roche signed a definitive agreement to acquire Poseida Therapeutics, a deal that includes Poseida’s portfolio of CAR T-cell therapy candidates being developed for multiple sclerosis (MS) and other diseases. Poseida and Roche have been collaborating since 2022 on cell therapies for people with blood cancer. The companies…

Higher cholesterol levels are associated with worse cognitive impairments in people with multiple sclerosis (MS), a study reported. The findings imply that medications or lifestyle changes that reduce cholesterol levels may be useful for addressing MS cognitive impairment, researchers said. The study, “Lipid measures are associated…